Peter Chambré

Peter Alan Chambré is Chairman at Cancer Research Technology Ltd. since 2011, Chairman at Immatics US, Inc. since 2012, Chairman at Immatics NV since 2021, Chairman at 7tm Holding ApS, Trustee at Cancer Research UK since 2016, and Trustee at Our Future Health Uk.
Former roles include Chief Executive Officer at MedImmune Ltd. from 2002 to 2006, Chief Executive Officer at Consort Medical Ltd., Chief Executive Officer at Cambridge Antibody Technology Group Ltd. from 2002 to 2006, Chairman at ApaTech Ltd. from 2008 to 2010, Chairman at Immatics Biotechnologies GmbH from 2012 to 2020, Chairman at Xellia Pharmaceuticals AS from 2008 to 2013, Chairman at Asker Healthcare Holding AB from 2011 to 2019, Chairman at 7TM A, Independent Non-Executive Director at Touchstone Innovations Ltd. from 2014 to 2017, Independent Non-Executive Director at UDG Healthcare Ltd. (Dublin), Independent Non-Executive Director at BTG Ltd. from 2006 to 2012, Independent Non-Executive Director at Spectris Ltd. from 2006 to 2016, Advisor at 3i Group Plc, Principal at Unilever Plc, Principal at Bain & Co., Inc., Chief Operating Officer at Celera Group, and Trustee at Cancer Research UK.
Education includes undergraduate studies at The University of Reading.